Personalizing Immune Checkpoint Inhibitor Therapy
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 2/23/2019 |
| Start Date: | February 2019 |
| End Date: | January 8, 2020 |
| Contact: | Rakesh Sindhi, MD |
| Email: | rakesh.sindhi@chp.edu |
| Phone: | 412-977-6141 |
Personalizing Immune Checkpoint Inhibitor Therapy for Solid Tumors
This prospective, observational study will evaluate whether vitro testing of tumor tissue and
white blood cells from patients with lung cancer who are being treated with immune checkpoint
inhibitors and other standard of care approaches, predicts clinical response to these agents.
white blood cells from patients with lung cancer who are being treated with immune checkpoint
inhibitors and other standard of care approaches, predicts clinical response to these agents.
Overall Goal: The long-term goal of this study is to predict whether checkpoint inhibitors
will be effective in individual patients with solid tumors.
Objectives: In this pilot study to be conducted in ten subjects with lung cancer who are to
receive checkpoint inhibitors, we will use cellular and molecular techniques to characterize
- tumor immunogenicity
- anti-tumor T-cell response
- effect of checkpoint inhibitors on antigen presentation and T-cell response, and
- the tumor microenvironment
Planned enrollment:
• Ten subjects with lung cancer
Methods for Informed Consent:
Investigators will approach subjects for informed consent
will be effective in individual patients with solid tumors.
Objectives: In this pilot study to be conducted in ten subjects with lung cancer who are to
receive checkpoint inhibitors, we will use cellular and molecular techniques to characterize
- tumor immunogenicity
- anti-tumor T-cell response
- effect of checkpoint inhibitors on antigen presentation and T-cell response, and
- the tumor microenvironment
Planned enrollment:
• Ten subjects with lung cancer
Methods for Informed Consent:
Investigators will approach subjects for informed consent
Inclusion Criteria:
- Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the
intent to receive therapy with immune checkpoint inhibitors
- Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy
- Informed consent
Exclusion Criteria:
• Lack of informed consent
We found this trial at
1
site
Click here to add this to my saved trials
